Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419532 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT04419532 is a Phase 1 study of Solid Tumor and Advanced Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 40 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT04419532, a Phase 1 study of Solid Tumor and Advanced Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
Conditions Studied
Interventions
- DRUG DS-1055a
Study Locations (6)
Other
- National Cancer Center Hospital - Chūōku
- National Cancer Center Hospital East - Kashiwa
- Cancer Institute Hospital of JFCR - Kōtoku
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati Cancer Center - Cincinnati
Ontario
- Princess Margaret Cancer Center - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419532
The ClinicalTrials.gov registry entry for NCT04419532 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (82% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which DS-1055a is the first listed.
NCT04419532 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT04419532 about?
NCT04419532 is a clinical study titled "A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
What is the current status of trial NCT04419532?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-10-09. Estimated completion is 2027-07-01.
What conditions does trial NCT04419532 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Solid Tumor.
What interventions are being tested in trial NCT04419532?
The interventions under investigation include: DS-1055a (DRUG).
Who is sponsoring clinical trial NCT04419532?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04419532 being conducted?
This trial has 6 study locations across New York, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.